Journal article

Pharmacological and host considerations surrounding dose selection and duration of therapy with echinocandins

C Fen Neoh, DCM Kong, MA Slavin, SCA Chen

Current Fungal Infection Reports | SPRINGER | Published : 2012

Abstract

Caspofungin, micafungin and anidulafungin are antifungal drugs with excellent safety profiles. Dosing regimens and treatment durations must be appropriate for optimal patient outcomes. Overall, factors that affect dosing of all three drugs are similar. Drug-specific properties, including in vitro concentration-dependent antifungal activity, activity against fungal biofilms, and pharmacokinetic and pharmacodynamic parameters influence dose selection and duration of therapy. Dosing strategies that provide "unbound" plasma drug concentrations exceeding the minimum inhibitory concentration (or minimum effective concentration) of the fungus are essential. Patient weight, age and illness severity ..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

Dr. S. Chen and Dr. M. Slavin has worked as a consultant for the Antifungal Advisory Board, Pfizer Australia, and the Antifungal Advisory Board, Merck; Dr. D.C. M Kong has received research grants from NHMRC, Gilead Sciences, CASS Foundation, PDL Ltd, Department of Health and Aging, Pharmacy Guild, and FRED and travel support from Pfizer; Dr. M. Slavin reported no potential conflicts of interest relevant to this article.